AIN
The End of Nicotine

The End of Nicotine

location_on South West ,  United Kingdom

The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. Investors should carry out their own due diligence and take professional advice where necessary.

Short Summary

ARO Labs is tackling the nicotine epidemic with NOQA, a nicotine-free inhalator designed to replace vaping and smoking. We’re raising £150k - £200K to complete launch readiness and capture a fast-growing global cessation market.

Highlights

  • Tackling the £50B nicotine epidemic with the world’s first true alternative
  • Manufacturing, supply & brand complete, ready for Q1 2026 launch
  • Clinically aligned, NHS-backed research validating addiction outcomes
  • Built to scale fast, global exit potential across health & tobacco sectors
  • Building a multi-product ecosystem tackling addiction through tech & habit

Overview

Target £150,000
Minimum £10,000
Investment Raised £0
Previous Rounds £0
Stage MVP/Finished Product
Investor Role Monthly Involvement

Ask a question
Got a question about this project?

Similar Projects

This promotion is exempt from the general restriction in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds it is made exclusively to ‘investment professionals’ within the meaning of Article 19 of the Financial Services and Markets Act (Financial Promotion) Order 2005 (FinProm); persons believed on reasonable grounds to be ‘certified high net worth individuals’ within the meaning of Article 48 FinProm; persons who are ‘certified sophisticated investors’ within the meaning of Article 50 FinProm; and persons who are ‘self-certified sophisticated investors’ within the meaning of Article 50A FinProm.

If you are in any doubt about the investment to which this email relates, you are strongly recommended to consult an appropriately authorised financial adviser qualified to give advice in relation to investment. This investment opportunity will not necessarily be suitable for all recipients of this email. Applications to subscribe for shares will only be accepted at the company's discretion from persons eligible to invest.